Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...

Finally, add Recursion Pharmaceuticals (NASDAQ: RXRX) to your list of growth stocks to invest in right now if you've got $1,000 you're ready to put to work and don't mind taking a little risk.

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...

The support network that has emerged through the Mises Institute is really important. We feel like we’re all alone, but ...